PAVE in Latin America: Introduction and Updates

November 14, 2023

Elodie Jambert, MMV

Jamil Barton, PATH

PAVE is an umbrella for MMV / PATH supported *P. vivax* initiatives

PAVE facilitates access to new and existing malaria diagnostics and treatments for *P. vivax* elimination.

Our goal is to support countries in accelerating the elimination of *P. vivax* malaria.

	Day	1	2	3	4	5	6	7
7*/14 DAY TREATMENT	PQ Week 1	●	●	●	●	●	●	●
	Week 2	●	●	●	●	●	●	●
	CQ/ACTs	■	■	■	*option for 7 day 0.5mg/kg/day			
3 DAY TREATMENT	TQ	●						
	CQ	■	■	■				

Standard malaria test   Quantitative G6PD test

Improving *P. vivax* outcomes

PAVE supports countries in achieving their elimination goals through:

▪ working with National Malaria Programmes to identify optimal radical cure tool options and strategies for their given contexts to achieve higher patient coverage.

▪ generating and making available high-quality evidence on *P. vivax* case management that can be considered by national governments in making policy decisions and guiding implementation.

▪ advancing the development of quality-assured, child-friendly treatments for relapse prevention.

PAVE

How PAVE is addressing these challenges

- PAVE is working to ensure access to G6PD testing, tafenoquine, and primaquine for adults and children across *P. vivax* endemic countries. PAVE is accomplishing this through engagement with NMCPs to increase knowledge of tools, support policy change, procurement, and roll-out of products.

- PAVE is also supporting feasibility studies and operational research looking at the best way to use these tools at different levels of the healthcare system in endemic countries.

- PAVE is engaging stakeholders at various levels in more than 15 countries across the major *P. vivax* endemic regions.

PAVE

PAVE Priority Countries

Legend:
- Scale-up
- Market Entry
- Strategy Creation
- Landscaping
- ● PAVE Feasibility Studies/ Operational Research

Map labels: Peru, Brazil, Ethiopia, India, Lao PDR, Vietnam, Thailand, Indonesia, PNG

Process: Market Landscaping → Strategy Creation → Launch Planning → Market Entry → Scale-Up

PAVE

PAVE progess towards scale-up

Market Landscaping	Strategy Creation	Launch Planning	Market Entry	Scale up

14 country landscapes completed

7 readiness workshops held

7 TQ & PQ Feasibility studies in process

2 countries initiating G6PD introduction

2 countries scaling radical cure & G6PD Dx

Brazil, Cambodia, Colombia, Ethiopia, Indonesia, Lao PDR, Myanmar, Pakistan, Papua New Guinea, Peru, Thailand, Sudan, Venezuela, Vietnam

Myanmar, Lao PDR, Vietnam, Cambodia, Peru

Pakistan and PNG (readiness workshop managed by APMEN VxWG)

TQ: Brazil (completed), Thailand and Peru (on-going), Ethiopia and Vietnam (planned)
PQ: Indonesia, PNG (planned)

3 Qn-G6PD studies completed or in process

Lao PDR (G6PD & PQ)
Vietnam (G6PD & PQ)
Colombia (G6PD training)

Thailand (G6PD & PQ)
Vietnam (planned intro in 2023 w/ G6PD & PQ)

Peru – TQ in EML; G6PD and TQ policy adoption in progress (Q4 '23) ahead of feasibility study

Brazil – CONITEC approval paves way for national adoption

Cambodia (G6PD & PQ)
Lao PDR (G6PD & PQ)

PAVE

PAVE Activities and Milestones in Latin America, 2022 & 2023

COLOMBIA

- Launch of Pilot Education Program (PEP)
- Economic Health Studies

- Finalization of the PEP
- Pilot implementation of G6PD testing
- Signed MoU between MSPS, MMV and PATH

GUATEMALA, HONDURAS y PANAMÁ

- Evaluation of Case Management for *P. vivax*

- Health Registration for new tools
- Pilot implementation of G6PD testing
- Multi-year planning for the adoption of new tools

BRAZIL

- Feasibility study, G6PD + TQ/PQ
- Health Economic Studies
- Dossier for the inclusion of new tolos into the Brazil's Single Health System (SUS)

- Formal Introduction of new tolos into the Brazil's Single Health System (SUS) with CONITEC appoval

PERU

- Inclusion of TQ into the Essential Medicines List

- Update of National Treatment Guidelines
- Health Economic Studies
- Feasibilty study, G6PD + TQ/PQ

PAVE

The way forward

- **Technical Support** for partners interested in developing malaria elimination interventions

- Completion of and access to **training and educational materials** from PAVE projects

- **PAVE Regional Meetings** in 2024 and 2025

- Advancing Access to **prediatric formulations of radical cure** (pTQ and pPQ)

- Completion and dissemination of **Peru's Feasibility Study** results

- Regular updates and exchange with key actors in Latin America's malaria ecosystem, especially National Malaria Programs and international partners

PAVE

Gracias

We would additionally like to acknowledge all our donors for their support

PAVE

Estados Regulatorios

Regional/Latinoamérica	Pais	Cura Radical (0.25g/kg)	Registro Sanitario			Guías de Práctica Clinica		Lista de Medicamentos Esenciales
		Actual	SDB	TQ	pTQ	SDB	TQ	TQ
	Brasil	PQ7d	✓	✓	✓	✓	✓	✓
	Colombia	PQ14d	✓	✓	En marcha	✓	_	_
	Guatemala	PQ14d	✓	En marcha	_	✓	_	_
	Honduras	PQ14d / PQ7d	✓	En marcha	_	✓	_	_
	Panama	PQ14d / PQ7d	✓	En marcha	_	✓	_	_
	Peru	PQ7d	✓	✓	En marcha	✓	En marcha	✓

Global	TQ	STANDARD Diagnóstico Biosensor (SDB)
	✓ FDA de EEUU: Jul 2018 ✓ TGA de Australia: Sep 2018 ✓ TGA de Australia: Mar 2022 (pediátrica) • WHO Pre-qualification: en marcha	✓ TGA de Australia: Abr 2021 ✓ ERPD con GF hasta 2024 • WHO Pre-qualification: en marcha

PAVE